Print

Biotechnology Industry Organization (BIO) Statement on U.S. Supreme Court Review of Isolated DNA Patents  
6/14/2013 10:22:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WASHINGTON--(BUSINESS WIRE)--Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on the U.S. Supreme Court's decision regarding Myriad Genetics' patent claims on isolated DNA molecules: “The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting. cDNA is the commercially most important form of DNA used in biotechnology. Today’s decision offers urgently-needed certainty for research-driven companies that rely on cDNA patents for investment in innovation. "In other respects, however, the Supreme Court's decision today represents a troubling departure from decades of judicial and Patent and Trademark Office precedent supporting the patentability of DNA molecules that mimic naturally-occurring sequences. In addition, the Court’s decision could unnecessarily create business uncertainty for a broader range of biotechnology inventions.

Help employers find you! Check out all the jobs and post your resume.

//-->